Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Vicky TC Chan & Winnie Yeo. (2011) Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. Breast Cancer: Targets and Therapy 3, pages 151-160.
Read now
Read now
Rudolph M Navari. (2009) Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Expert Opinion on Drug Metabolism & Toxicology 5:12, pages 1577-1586.
Read now
Read now
Rudolph M Navari. (2009) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy. Cancer Management and Research 1, pages 167-176.
Read now
Read now
Rudolph M Navari. (2008) Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Review of Anticancer Therapy 8:11, pages 1733-1742.
Read now
Read now
Jennifer LaRusso, Scott A Waldman & Walter K Kraft. (2008) Aprepitant for the prevention of nausea and vomiting associated with chemotherapy and postoperative recovery. Expert Review of Clinical Pharmacology 1:1, pages 27-37.
Read now
Read now
Mellar P Davis. (2008) Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opinion on Investigational Drugs 17:1, pages 85-95.
Read now
Read now
Rudolph M Navari. (2007) Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opinion on Investigational Drugs 16:12, pages 1977-1985.
Read now
Read now
Articles from other publishers (18)
Yu-Chen Hsu, Ching-Yao Chen, Ka-Wai Tam & Chin-Yu Hsu. (2021) Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. European Journal of Clinical Pharmacology 77:11, pages 1597-1609.
Crossref
Crossref
Alisha Moreland-CapuiaAlisha Moreland-Capuia. 2019. Training for Change. Training for Change
147
171
.
Rajni Bala & Shailesh Sharma. (2018) Formulation optimization and evaluation of fast dissolving film of aprepitant by using design of experiment. Bulletin of Faculty of Pharmacy, Cairo University 56:2, pages 159-168.
Crossref
Crossref
Faaiza Shahid, Zeba Farooqui & Farah Khan. (2018) Cisplatin-induced gastrointestinal toxicity: An update on possible mechanisms and on available gastroprotective strategies. European Journal of Pharmacology 827, pages 49-57.
Crossref
Crossref
Jeffrey S. Barrett, Sergei Spitsin, Ganesh Moorthy, Kyle Barrett, Kate Baker, Andrew Lackner, Florin Tulic, Angela Winters, Dwight L. Evans & Steven D. Douglas. (2016) Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV. Journal of Translational Medicine 14:1.
Crossref
Crossref
Kevin Yi-Lwern Yap, Xiu Hui Low & Alexandre Chan. (2012) Exploring Chemotherapy-Induced Toxicities through Multivariate Projection of Risk Factors: Prediction of Nausea and Vomiting. Toxicological Research 28:2, pages 81-91.
Crossref
Crossref
Tobias Engel Ayer Botrel, Otávio Augusto C. Clark, Luciana Clark, Luciano Paladini, Enéas Faleiros & Bruna Pegoretti. (2010) Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Supportive Care in Cancer 19:6, pages 823-832.
Crossref
Crossref
N. Licup & S. Baumrucker. (2010) Olanzapine for Nausea and Vomiting. American Journal of Hospice and Palliative Medicine 27:6, pages 432-434.
Crossref
Crossref
Rudolph M Navari. (2010) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncology 6:7, pages 1073-1084.
Crossref
Crossref
Quan LiJulianna V.F. RoddyMichael Berger. (2009) Palonosetron Hydrochloride in the Treatment of Chemotherapy-Induced Nausea and Vomiting. Clinical Medicine. Therapeutics 1, pages CMT.S2179.
Crossref
Crossref
Lisa Lohr. (2008) Chemotherapy-Induced Nausea and Vomiting. The Cancer Journal 14:2, pages 85-93.
Crossref
Crossref
Michel Beauverd, Sophie Pautex & José Pereira. (2008) Place des neuroleptiques atypiques dans la prise en charge du delirium et des nausées chez le patient palliatif. InfoKara Vol. 22:4, pages 95-103.
Crossref
Crossref
Yumi Watanabe, Hidetoshi Asai, Taketoshi Ishii, Satoko Kiuchi, Masahito Okamoto, Hiroyuki Taniguchi, Masaaki Nagasaki & Akira Saito. (2008) Pharmacological Characterization of T-2328, 2-Fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile Dihydrochloride, as a Brain-Penetrating Antagonist of Tachykinin NK1 Receptor. Journal of Pharmacological Sciences 106:1, pages 121-127.
Crossref
Crossref
Yumi Watanabe, Masahito Okamoto, Taketoshi Ishii, Satomi Takatsuka, Hiroyuki Taniguchi, Masaaki Nagasaki & Akira Saito. (2008) Long-Lasting Anti-emetic Effect of T-2328, a Novel NK1 Antagonist. Journal of Pharmacological Sciences 107:2, pages 151-158.
Crossref
Crossref
Heiko Zettl, Manfred Schubert‐Zsilavecz & Carsten D. Siebert. (2007)
Medizinische Chemie der 5‐HT
3
‐Rezeptor‐Antagonisten. Vom Cocain zu innovativen Antiemetika
. Pharmazie in unserer Zeit 36:5, pages 354-361.
Crossref
Crossref
Aarati Ranganathan, Sabeeha Muneer, Sonia Cunningham, Latha Shivakumar & Debu Tripathy. (2007) Highlights from: The 24th Annual Miami Breast Cancer Conference; Miami, FL; March 14–17, 2007. Supportive Cancer Therapy 4:3, pages 137-144.
Crossref
Crossref
Rudolph M Navari. (2006) Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncology 2:5, pages 591-602.
Crossref
Crossref
Edward B. Rubenstein, Barbara S. Slusher, Camilo Rojas & Rudolph M. Navari. (2006) New Approaches to Chemotherapy-Induced Nausea and Vomiting. The Cancer Journal 12:5, pages 341-347.
Crossref
Crossref